Enbezotinib
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID | |
Chemical and physical data | |
Formula | C21H21FN6O3 |
Molar mass | 424.436 g·mol−1 |
3D model (JSmol) | |
| |
|
Enbezotinib (TPX-0046) is an experimental anticancer medication which acts as a RET inhibitor, as well as an inhibitor of SRC kinase.[1][2]
See also
[edit]References
[edit]- ^ Repetto M, Crimini E, Ascione L, Boscolo Bielo L, Belli C, Curigliano G (October 2022). "The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046". Investigational New Drugs. 40 (5): 1133–1136. doi:10.1007/s10637-022-01259-x. PMID 35612671. S2CID 246502280.
- ^ Gou Q, Gan X, Li L, Gou Q, Zhang T (December 2022). "Precious Gene: The Application of RET-Altered Inhibitors". Molecules (Basel, Switzerland). 27 (24): 8839. doi:10.3390/molecules27248839. PMC 9784389. PMID 36557971.